Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic
British Journal of Dermatology2020Vol. 183(2), pp. 404–406
Citations Over TimeTop 10% of 2020 papers
Satveer K. Mahil, Zenas Z N Yiu, K.J. Mason, Nick Dand, Bola Coker, Dmitri Wall, G. Fletcher, Angela L. Bosma, Francesca Capon, Lars Iversen, Sinéad Langan, Paola Di Meglio, Annelie H. Musters, David Prieto‐Merino, Teresa Tsakok, Richard B. Warren, Carsten Flohr, Phyllis I. Spuls, C.E.M. Griffiths, Jessica L. Barker, Alan D. Irvine, Catherine Smith, the Secure‐AD and PsoProtect study groups
Abstract
We read with interest the article in the BJD by Gambichler and colleagues 1 about a decline of programmed death (PD)-1 + circulating T regulatory cells (Tregs) predicting clinical outcome in anti-PD-1 therapy. The study highlights the potential and importance of immune monitoring in anti-PD-1 checkpoint therapy in malignant melanoma.
Related Papers
- → Natalizumab treatment reduces endothelial activity in MS patients(2010)35 cited
- → No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation(2014)26 cited
- → Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis(2023)3 cited
- → Natalizumab in multiple sclerosis: proceed with caution?(2006)3 cited
- → Natalizumab: a promising treatment for Crohn’s disease(2006)1 cited